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GTPases of the Rho subfamily are widely involved in the myelination of the vertebrate nervous system. Rho GTPase
activity is temporally and spatially regulated by a set of specific guanine nucleotide exchange factors (GEFs). Here, we
report that disruption of frabin/FGD4, a GEF for the Rho GTPase cell-division cycle 42 (Cdc42), causes peripheral nerve
demyelination in patients with autosomal recessive Charcot-Marie-Tooth (CMT) neuropathy. These data, together with
the ability of frabin to induce Cdc42-mediated cell-shape changes in transfected Schwann cells, suggest that Rho GTPase
signaling is essential for proper myelination of the peripheral nervous system.
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Charcot-Marie-Tooth (CMT) disease comprises a group of
clinically and genetically heterogeneous hereditary motor
and sensory neuropathies (HMSNs). With an overall pop-
ulation prevalence of 1 in 2,500, CMT constitutes the most
common inherited neuromuscular disorder.1 Clinical fea-
tures comprise progressive distal muscle weakness and at-
rophy, foot deformities, and distal sensory loss. Two major
subtypes have been discerned by electrophysiological and
peripheral nerve biopsy studies: the demyelinating form
(CMT1 or HMSN I) and the axonal type (CMT2 or HMSN
II). CMT1 is characterized by reduced nerve conduction
velocities (NCVs), segmental demyelination and remye-
lination, and onion bulb formation in nerve biopsy spec-
imens. Patients with CMT2 present with near-normal
NCVs but with reduced amplitudes of compound motor
and sensory action potentials and with loss of myelinated
axons and signs of axonal degeneration in nerve biopsy
specimens.2 Both types of CMT are genetically heteroge-
neous, with autosomal dominant, X-linked, and autoso-
mal recessive inheritance. In recent years, considerable
advances have been made in the understanding of the
molecular genetics of CMT neuropathies. Mutations of
genes that cause CMT are listed in the Inherited Peripheral
Neuropathy Mutation Database.
Gene mutations causing demyelinating CMT1 affect the
development, maintenance, and function of the Schwann
cells, which effect myelination in the peripheral nervous
system (PNS).3–5 Schwann cells are highly specialized cells
that need to exert a multitude of tightly regulated cellular
activities, such as proliferation, migration, adhesion, po-
larization, and vesicle and membrane trafficking.6,7 All
these processes involve the actin cytoskeleton and the mi-
crotubule network of the cell. Both actin and microtubule
dynamics are controlled through small GTPases of the
Rho family.8 Like all GTPases, Rho proteins cycle between
an inactive (GDP-bound) and an active (GTP-bound) con-
formational state. Interconversion and accessibility of
these two forms are temporally and spatially regulated in
a variety of ways.9 Guanine nucleotide exchange factors
(GEFs) stimulate the exchange of GDP for GTP, to generate
the activated form, which then modulates the activity of
downstream targets and effector molecules. GTPase-acti-
vating proteins (GAPs) accelerate the intrinsic GTPase ac-
tivity of Rho family members and terminate the signal-
transduction process. Finally, guanine nucleotide dissoc-
iation inhibitors (GDIs) control cycling of GTPases be-
tween membranes and cytosol. Overall, Rho GTPases and
their regulators are promising candidates for molecules
that control several aspects of Schwann cell biology, in-
cluding those associated with the ensheathment and my-
elination of axons. Interestingly, a missense mutation in
the gene for a putative Rho GTPase GEF, ARHGEF10, is
associated with a dominant trait of slowed NCVs and
thin myelin sheaths, without clinical CMT phenotype in
humans.10
To increase the understanding of the role of Rho
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Figure 1. FGD4 mutations in the four families with CMT4H. Ar-
rowheads in the electropherograms indicate the disease-causing
mutations. The wild-type sequence is shown in the lower electro-
pherogram in each panel. A, Homozygous nonsense mutation
c.670CrT, R224X. B, Homozygous missense mutation c.893TrG,
M298R. C, Homozygous frameshift mutation c.1626_1627delAG,
E543fs. The reverse sequence is shown. An arrow indicates the
frameshift. D, Homozygous nonsense mutation c.1756GrT, G586X.
Figure 2. In silico characterization of the consequences of the
c.893TrG mutation in the FGD4 gene. A, Multiple sequence align-
ment, generated with ClustalW, of the protein region surrounding
the site of the putative M298R mutation. Conserved residues are
shown on a gray background. M298R (in bold) is conserved through
evolution in members of the FGD protein family. B, Scores from
different splice-site prediction algorithms (i.e., WebGene, NNSpl-
ice, FSPLICE, and SPL). The putative donor splice site created by
the c.893TrG change reaches scores similar to the genuine intron
7 donor splice site.
GTPase signaling in the PNS, we combined positional and
functional cloning strategies. Using the UCSC Genome
Browser, we systematically investigated critical linkage in-
tervals of CMT forms for which no disease genes had been
identified so far (CMT2B2 [MIM %605589], CMT4H [MIM
%609311], HMSNR [MIM %605285], CMTDIA [MIM
%606483], CMT2G [MIM %608591], and CMT2C [MIM
%606071]), to search for the presence of genes encoding
Rho GTPases or Rho GTPase regulatory proteins. The most
striking candidate was the FGD4 gene (GenBank accession
number NM_139241), which was identified within the
11.5-cM critical interval for CMT4H on chromosome
12p11.21-q13.11. The FGD4 gene encodes frabin, a GEF
for the Rho GTPase cell-division cycle 42 (Cdc42).11,12
CMT4H is an autosomal recessive demyelinating form of
CMT that was initially mapped in Lebanese and Algerian
consanguineous families.13 All patients had early disease
onset but slowly progressive sensorimotor neuropathy,
and most of them presented with severe scoliosis. NCVs
were invariably slow, and sural nerve biopsy specimens
displayed a severe loss of myelinated fibers, thinly mye-
linated axons, and outfoldings of myelin sheaths. To es-
tablish the causative role of FGD4 in CMT4H, we selected
a series of 63 patients with demyelinating sensorimotor
neuropathy with onset in the 1st decade, absence of clin-
ical symptoms and neurophysiological signs in the par-
ents, and at least one of the following features: (i) parental
consanguinity or at least one other affected sibling, (ii)
severely slowed NCVs (!15 m/s for the motor median
nerve), (iii) prominent scoliosis, and (iv) myelin outfold-
ings in nerve biopsy specimens.
We used primers (generated with Primer3 software)
flanking the 15 coding exons of the FGD4 gene, to amplify
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Figure 3. Expression analysis and overexpression of Fgd4/frabin in Schwann cells. A, Western-blot analysis of lysates from rat tissues,
Schwann cell lines, and cultured primary Schwann cells. Upper panel, Mouse monoclonal anti-frabin antibody (BD Transduction Labs)
detecting a band of the expected size in all lysates analyzed. Lower panel, Blot probed with mouse monoclonal anti–b-actin antibody
(Sigma-Aldrich) to ensure similar loading. Lane 1, Spinal cord; lane 2, sciatic nerve; lane 3, whole brain; lane 4, primary rat Schwann
cells; lane 5, primary rat oligodendrocytes; lane 6, RN22; and lane 7, RT4-D6P2T. B, Quantitative RT-PCR analysis of Fgd4 (GenBank
accession number NM_139232) expression in the developing mouse sciatic nerve. Measurements were normalized against Gapdh levels.
p p Postnatal days. C, Frabin-induced cell-shape changes of primary rat Schwann cells. Upper panel, overview; lower panel, detail of
cell processes. pCMV-Myc full-length frabin was transfected by use of the liposome-mediated gene transfection. Left, Transfected cells
identified by staining with a mouse monoclonal anti-myc antibody (Roche Diagnostics) and a Cy3-conjugated goat anti-mouse antibody
(red) (Jackson ImmunoResearch). Middle, Actin cytoskeleton, visualized with Alexa Fluor 488 phalloidin (green) (Molecular Probes).
Right, Merge. Arrows indicate filopodia; arrowheads indicate lamellipodia. Note that untransfected cells, visible in the middle and right
columns, are virtually devoid of filopodia and lamellipodia.
genomic DNA of affected individuals, and products were
subjected to direct sequencing. We identified homozygous
mutations in the FGD4 gene in three consanguineous fam-
ilies and in one patient with sporadic disease (fig. 1). Three
of the identified mutations are clearly pathogenic, because
they result in premature stop codons at amino acids 224
and 586 and in a frameshift at amino acid 543. The fourth
mutation is also most likely pathogenic, since it is pre-
dicted to result in a nonconservative substitution of an
evolutionarily conserved amino acid at position 298. Al-
ternatively, according to in silico splice-site predictions, it
may create a new donor splice site that would remove part
of exon 7 from the mature cDNA and result in a frame
shift (fig. 2). Unfortunately, no fresh blood sample was
obtainable for mRNA isolation, for the further pursuit of
this possibility. We confirmed cosegregation of the DNA
changes with the phenotype in all four families. The par-
ents carried these mutations in the heterozygous state,
whereas unaffected siblings also carried one mutation or
were homozygous for the wild-type alleles. These muta-
tions have not been described previously in the National
Center for Biotechnology Information dbSNP database, in
which information on human genome variation is de-
posited, and none of these changes was detected in the
DNA of healthy control samples (100 control DNA sam-
ples of western European origin for the truncating mu-
tations and 300 western European and 160 ethnically
matched control samples for the putative missense
change). Clinical, electrophysiologic, and morphological
data of patients with identified FGD4 mutations are sum-
marized in table 1.
The FGD4 gene product, frabin, is a 766-aa protein with
a molecular mass of 105 kDa.11 Frabin has, in order from
the N- to the C- terminus, one F-actin binding (FAB) do-
main, a Dbl homology (DH) domain in tandem with a
pleckstrin homology (PH) domain, a FYVE finger (FYVE)
domain, and a second PH domain. The adjacent DH and
PH domains are the typical signatures of GEFs for Rho
GTPases. Therefore, it is not surprising that frabin was
found to act as a GEF for the Rho GTPase Cdc42.12 In
line with this observation, overexpression of frabin in
various cell types results in Cdc42-mediated cell-shape
changes.11,12,14–16 Its domain structure and composition
place frabin in the small family of orthologues of the FGD1
protein. FGD1 is mutated in faciogenital dysplasia (also
known as Aarskog syndrome [MIM #305400]), a form of
syndromic X-linked mental retardation.17 FGD1 also acts
as a GEF specific to Cdc42,18 but patients with Aarskog
syndrome do not have peripheral neuropathy, and the
mental status of patients with CMT4H is normal. This
highlights the fact that different FGD proteins are not
interchangeable and that sets of cooperating Rho GTPases
and FGD proteins may be tissue- or cell-type specific.
To establish the role of frabin in the PNS, we studied its
expression in developing and adult rodent sciatic nerve,
in rat Schwann cell lines, and in rat primary Schwann cell
cultures. Frabin is expressed during early postnatal devel-
opment of the PNS. Expression persists in adult sciatic
nerve, and both Schwann cell lines (RT4-D6P2T and
RN22) as well as primary cultures of Schwann cells express
frabin (fig. 3). These expression data are consistent with
the tissue and the cell population involved in a demye-
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Figure 4. Sural nerve biopsy specimens of patients with FGD4
mutations. A, Transverse section of the sural nerve biopsy sample
of patient CMT244 with the FGD4 M298R mutation. There is a
moderate decrease in density of myelinated fibers, particularly
affecting the large fibers. Many of the remaining fibers are thinly
myelinated, whereas others are surrounded by thickened, grossly
distorted, and excessively folded myelin. Toluidine blue staining;
400# magnification. B, Teased fiber preparation of the sural nerve
biopsy sample of the same patient. There are demyelinated seg-
ments and myelin thickenings on virtually every fiber. 100#
magnification. C and D, Electron micrographs of the sural nerve
biopsy specimen of patient NP447 with the FGD4 E543fs mutation.
Complex folding of the myelin sheath outside the axon (C and D)
and a loop extending toward the axon (C) are shown. Semithin
sections stained with uranyl acetate and lead citrate; 6,500#
magnification.
linating peripheral neuropathy. We next addressed the
question of whether frabin also exerts its known functions
in Schwann cells. To this end, we transiently expressed
myc-tagged frabin (a kind gift from Y. Takai) in Schwann
cell lines and primary Schwann cells. Frabin was capable
of altering the cell shape in Schwann cells and induced
the formation of prominent filopodia and lamellipodia
(fig. 3), similar to the effect of a constitutive active form
of Cdc42 (also a kind gift from Y. Takai).11,12 These results
suggest that frabin is biologically active in Schwann cells.
The particular relevance of Rho GTPase signaling through
Cdc42 for myelinating glial cells has very recently been
shown in oligodendrocytes, the counterparts of Schwann
cells in the CNS. Oligodendrocyte-specific conditional
gene ablation of Cdc42 in mice results in severe myelin
abnormalities in the CNS.19 Moreover, the phenotype of
the conditional knockout of Cdc42 activity in Schwann
cells indicates that Cdc42 is necessary for Schwann cell
proliferation and the correct myelination of axons in the
murine PNS (J.B.R. and U.S., unpublished data). These data
strongly support our conclusion that CMT4H is a disease
of impaired Rho GTPase signaling.
The presence of FYVE and PH domains in frabin suggests
cooperation of frabin with another group of CMT pro-
teins, the myotubularin-related proteins MTMR2 (MIM
*603557) and SET binding factor 2 (SBF2/MTMR13 [MIM
*607697]). MTMRs are a family of phosphoinositide phos-
phatases that are believed to control spatial and temporal
phosphoinositide phosphate (PIP) pools on cellular mem-
branes.20–23 FYVE and PH domains are known to bind to
PIPs, and it has been shown that localization and nucle-
otide-exchange activity of Rho GTPase GEFs are regulated
by their association with specific PIPs.24–26 Thus, it is pos-
sible that binding to MTMR substrates and products reg-
ulates the spatial and temporal activity of frabin and, by
extension, Cdc42 in Schwann cells. Confirmation of this
hypothesis will require measurement of interactions be-
tween PIPs and frabin PH domains, to identify those PIPs
to which frabin binds preferentially. Interestingly, the hy-
pothesis of a functional relationship between RhoGTPase
signaling and MTMRs is further supported by the occur-
rence of similar myelin abnormalities in the nerve biopsy
samples of affected patients. Patients with MTMR2 and
SBF2/MTMR13 mutations consistently display irregular
folding and redundant loops of myelin—so-called myelin
outfoldings27—and we observed similar irregularities of
the myelin sheaths in the nerve biopsy specimens of two
patients with FGD4 mutations (fig. 4). The formation of
myelin outfoldings suggests dysregulation of membrane-
transport processes in the diseased Schwann cells, prob-
ably related to impaired Rho GTPase signaling.
Overall, our study reveals a new disease-related mech-
anism in hereditary peripheral neuropathies. Our discov-
ery will aid genetics testing and counseling for patients
with CMT. Moreover, the knowledge about the involve-
ment of Rho GTPase signaling in an inherited neuropathy
provides a direct path to a better understanding of the
development, degeneration, and regeneration of the PNS.
Identification of the underlying mechanisms of Schwann
cell damage in inherited neuropathies may also hold
promise for the development of therapies not only for
these rare entities but also for a broad spectrum of more
frequent acquired demyelinating disorders of the PNS and
the CNS. In this way, our data are relevant for patient and
family care, basic science, and, we hope, future treatment
options.
Acknowledgments
We are indebted to the members of the families with CMT for
their participation in this study. We thank Y. Takai for the frabin
and Cdc42 constructs. C.S. is a postdoctoral fellow of the
Deutsche Forschungsgemeinschaft (DFG). J.P. is supported by the
Fundac¸a˜o para a Cieˆncia e a Tecnologia. U.S. received grants from
www.ajhg.org The American Journal of Human Genetics Volume 81 July 2007 163
the Swiss National Science Foundation and the National Center
of Competence in Research Neuro–Neural Plasticity and Repair.
V.T. and P.D.J. were supported by the Fund for Scientific Research
(FWO-Flanders), the Medical Foundation Queen Elisabeth, the
University of Antwerp, the Interuniversity Attraction Poles pro-
gram of the Belgian Federal Science Policy Office (BELSPO), and
the Association Belge contre les Maladies Neuromusculaires. J.
Senderek was supported by the START program of the Faculty of
Medicine of Aachen University of Technology and by grants from
the Doktor Robert Pfleger-Stiftung and the Maximilian May-Stif-
tung. This work was supported by a grant from the Interdisci-
plinary Centre for Clinical Research, “BIOMAT,” within the Fac-
ulty of Medicine of Aachen University of Technology (to J.W.,
A.K., and J. Senderek).
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
ClustalW, http://www.ebi.ac.uk/clustalw/
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/
FSPLICE, http://softberry.com/berry.phtml?topicpfsplice&group
pprograms&subgrouppgfind
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for Homo
sapiens FGD4 [accession number NM_139241] and Mus mus-
culus Fgd4 [accession number NM_139232])
Inherited Peripheral Neuropathy Mutation Database, http://www
.molgen.ua.ac.be/CMTMutations/
NNSplice, http://www.fruitfly.org/seq_tools/splice.html
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for CMT2B2, CMT4H, HMSNR, CMTDIA,
CMT2G, CMT2C, faciogenital dysplasia/Aarskog syndrome,
MTMR2, and SBF2/MTMR13)
Primer3, http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www
.cgi
SPL, http://softberry.com/berry.phtml?topicpspl&group
pprograms&subgrouppgfind
UCSC Genome Browser, http://genome.ucsc.edu/
WebGene, http://l25.itba.mi.cnr.it/˜webgene/wwwspliceview.html
References
1. Skre H (1974) Genetic and clinical aspects of Charcot-Marie-
Tooth disease. Clin Genet 6:98–118
2. Dyck PJ, Chance P, Lebo R, Carney JA (1993) Hereditary motor
and sensory neuropathies. In: Dyck PJ, Thomas PK, Griffin
JW, Low PA, Poduslo JF (eds) Peripheral neuropathy. WB
Saunders, Philadelphia, pp 1094–1136
3. Berger P, Niemann A, Suter U (2006) Schwann cells and the
pathogenesis of inherited motor and sensory neuropathies
(Charcot-Marie-Tooth disease). Glia 54:243–257
4. Niemann A, Berger P, Suter U (2006) Pathomechanisms of
mutant proteins in Charcot-Marie-Tooth disease. Neuromo-
lecular Med 8:217–242
5. Suter U, Scherer SS (2003) Disease mechanisms in inherited
neuropathies. Nat Rev Neurosci 4:714–726
6. Jessen KR, Mirsky R (2005) The origin and development of
glial cells in peripheral nerves. Nat Rev Neurosci 6:671–682
7. Lobsiger CS, Taylor V, Suter U (2002) The early life of a
Schwann cell. Biol Chem 383:245–253
8. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell bi-
ology. Nature 420:629–635
9. Boguski MS, McCormick F (1993) Proteins regulating Ras and
its relatives. Nature 366:643–654
10. Verhoeven K, De Jonghe P, Van de Putte T, Nelis E, Zwijsen
A, Verpoorten N, De Vriendt E, Jacobs A, Van Gerwen V, Fran-
cis A, et al (2003) Slowed conduction and thin myelination
of peripheral nerves associated with mutant Rho guanine-
nucleotide exchange factor 10. Am J Hum Genet 73:926–932
11. Obaishi H, Nakanishi H, Mandai K, Satoh K, Satoh A, Taka-
hashi K, Miyahara M, Nishioka H, Takaishi K, Takai Y (1998)
Frabin, a novel FGD1-related actin filament-binding protein
capable of changing cell shape and activating c-Jun N-ter-
minal kinase. J Biol Chem 273:18697–700
12. Umikawa M, Obaishi H, Nakanishi H, Satoh-Horikawa K, Tak-
ahashi K, Hotta I, Matsuura Y, Takai Y (1999) Association of
frabin with the actin cytoskeleton is essential for microspike
formation through activation of Cdc42 small G protein. J Biol
Chem 274:25197–25200
13. De Sandre-Giovannoli A, Delague V, Hamadouche T,
Chaouch M, Krahn M, Boccaccio I, Maisonobe T, Chouery E,
Jabbour R, Atweh S, et al (2005) Homozygosity mapping of
autosomal recessive demyelinating Charcot-Marie-Tooth
neuropathy (CMT4H) to a novel locus on chromosome
12p11.21-q13.11. J Med Genet 42:260–265
14. Yasuda T, Ohtsuka T, Inoue E, Yokoyama S, Sakisaka T, Ko-
dama A, Takaishi K, Takai Y (2000) Importance of spatial ac-
tivation of Cdc42 and rac small G proteins by frabin for mi-
crospike formation in MDCK cells. Genes Cells 5:583–591
15. Kim Y, Ikeda W, Nakanishi H, Tanaka Y, Takekuni K, Itoh S,
Monden M, Takai Y (2002) Association of frabin with specific
actin and membrane structures. Genes Cells 7:413–420
16. Nakahara H, Otani T, Sasaki T, Miura Y, Takai Y, Kogo M (2003)
Involvement of Cdc42 and Rac small G proteins in invado-
podia formation of RPMI7951 cells. Genes Cells 8:1019–1027
17. Pasteris NG, Cadle A, Logie LJ, Porteous ME, Schwartz CE,
Stevenson RE, Glover TW, Wilroy RS, Gorski JL (1994) Iso-
lation and characterization of the faciogenital dysplasia (Aar-
skog-Scott syndrome) gene: a putative Rho/Rac guanine nu-
cleotide exchange factor. Cell 79:669–678
18. Zheng Y, Fischer DJ, Santos MF, Tigyi G, Pasteris NG, Gor-
ski JL, Xu Y (1996) The faciogenital dysplasia gene product
FGD1 functions as a Cdc42Hs-specific guanine-nucleotideex-
change factor. J Biol Chem 271:33169–33172
19. Thurnherr T, Benninger Y, Wu X, Chrostek A, Krause SM,
Nave KA, Franklin RJ, Brakebusch C, Suter U, Relvas JB (2006)
Cdc42 and Rac1 signaling are both required for and act syn-
ergistically in the correct formation of myelin sheaths in the
CNS. J Neurosci 26:10110–10119
20. Berger P, Schaffitzel C, Berger I, Ban N, Suter U (2003)
Membrane association of myotubularin-related protein 2 is
mediated by a pleckstrin homology-GRAM domain and a
coiled-coil dimerization module. Proc Natl Acad Sci USA 100:
12177–12182
21. Berger P, Bonneick S, Willi S, Wymann M, Suter U (2002) Loss
of phosphatase activity in myotubularin-related protein 2 is
associated with Charcot-Marie-Tooth disease type 4B1. Hum
Mol Genet 11:1569–1579
22. Pendaries C, Tronchere H, Plantavid M, Payrastre B (2003)
Phosphoinositide signaling disorders in human diseases.
FEBS Lett 546:25–31
23. Berger P, Berger I, Schaffitzel C, Tersar K, Volkmer B, Suter U
(2006) Multi-level regulation of myotubularin-related pro-
164 The American Journal of Human Genetics Volume 81 July 2007 www.ajhg.org
tein-2 phosphatase activity by myotubularin-related protein-
13/set-binding factor-2. Hum Mol Genet 15:569–579
24. Han J, Luby-Phelps K, Das B, Shu X, Xia Y, Mosteller RD,
Krishna UM, Falck JR, White MA, Broek D (1998) Role of
substrates and products of PI 3-kinase in regulating activation
of Rac-related guanosine triphosphatases by Vav. Science 279:
558–560
25. Russo C, Gao Y, Mancini P, Vanni C, Porotto M, Falasca M,
Torrisi MR, Zheng Y, Eva A (2001) Modulation of oncogenic
DBL activity by phosphoinositol phosphate binding to pleck-
strin homology domain. J Biol Chem 276:19524–19531
26. Snyder JT, Rossman KL, Baumeister MA, Pruitt WM, Siderov-
ski DP, Der CJ, Lemmon MA, Sondek J (2001) Quantitative
analysis of the effect of phosphoinositide interactions on the
function of Dbl family proteins. J Biol Chem 276:45868–
45875
27. Dubourg O, Azzedine H, Verny C, Durosier G, Birouk N, Goui-
der R, Salih M, Bouhouche A, Thiam A, Grid D, et al (2006)
Autosomal-recessive forms of demyelinating Charcot-Marie-
Tooth disease. Neuromolecular Med 8:75–86
